Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

AIMS/HYPOTHESIS: Delayed-release metformin (Metformin DR) was developed to maximise gut-based mechanisms of metformin action by targeting the drug to the ileum. Metformin DR was evaluated in two studies. Study 1 compared the bioavailability and effects on circulating glucose and gut hormones (glucag...

Descripción completa

Detalles Bibliográficos
Autores principales: DeFronzo, Ralph A., Buse, John B., Kim, Terri, Burns, Colleen, Skare, Sharon, Baron, Alain, Fineman, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930485/
https://www.ncbi.nlm.nih.gov/pubmed/27216492
http://dx.doi.org/10.1007/s00125-016-3992-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930485/
https://www.ncbi.nlm.nih.gov/pubmed/27216492
http://dx.doi.org/10.1007/s00125-016-3992-6

Ejemplares similares